Cinven Moves Toward Nutrisens Acquisition Amid Global Expansion Goals

With operations in over 30 countries, Nutrisens specializes in medical nutrition solutions for vulnerable groups, including the elderly and chronically ill.

A Strategic Step into Clinical Nutrition

Cinven, the London-headquartered investment firm, has confirmed that it is in exclusive negotiations to acquire Nutrisens, a France-based clinical nutrition provider, from Sagard MidCap, a Canada-based private equity player. The potential deal also includes collaboration with Georges Devesa, the company’s founder and CEO, and the existing management team.

Established in 2011, Nutrisens develops and distributes a range of medical nutrition products tailored for individuals suffering from conditions such as malnutrition, dysphagia, muscle loss, and weight deficiency. These products are primarily aimed at the elderly and other medically vulnerable populations. The company has built a growing footprint across Europe and Latin America, including subsidiaries in Brazil, Spain, Italy, the UK, Germany, and Portugal, employing more than 750 people worldwide.

Cinven Sees Long-Term Value in Medical Nutrition

A representative from Cinven’s Healthcare Sector team, Pontus Pettersson, emphasized that the investment is driven by the size and durability of the medical nutrition market. He noted that Nutrisens' international presence, combined with its specialized product line and scalable structure, positions it well for future growth. He also pointed out that the company has demonstrated consistent double-digit organic growth in recent years while working to improve operational margins.

Pierre Estrade, who leads Cinven’s French regional operations, echoed these sentiments, stating that the company sees Nutrisens as well-positioned to strengthen its market presence not only in France, but globally. He added that Cinven aims to support Nutrisens in the next stage of its expansion journey.

Deal Highlights Cinven’s Healthcare Investment Focus

The pending acquisition reflects Cinven’s broader strategy to deepen its investments within the healthcare sector across Europe. Nutrisens represents an asset that aligns with Cinven’s interest in businesses serving aging populations and chronic health conditions. The company’s emphasis on clinical outcomes and specialized nutrition distinguishes it from general food and wellness providers.

As discussions progress under exclusive terms, the transaction is expected to close following regulatory approvals and customary closing conditions. If finalized, this acquisition would mark another step in Cinven’s growing healthcare portfolio and expand its reach within the clinical nutrition segment.